Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.53 |
| ▸ | MMP2 | P08253 | 6/20 | 0.53 |
| ▸ | MMP9 | P14780 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160235 | 1.00 | SLC1A3 (0.59) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL7402563 | 1.00 | SLC1A3 (0.59) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL6668234 | 0.87 | ITGB3 (0.67) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL5502396 | 0.87 | ITGB3 (0.67) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL6093215 | 0.87 | ITGB3 (0.67) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL6671273 | 0.85 | SLC1A3 (0.57) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL8798534 | 0.85 | SLC1A3 (0.57) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL6671271 | 0.85 | SLC1A3 (0.57) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL3898276 | 0.85 | SLC1A3 (0.57) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL7373819 | 0.85 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059738-B2 | Process for the production of a dipeptide derivative | DSM IP ASSETS B.V. (NL) | 2018-08-28 | — | — | US | disclosed |
| EP-3160939-B1 | PROCESS FOR THE PRODUCTION OF A DIPEPTIDE DERIVATIVE | DSM IP ASSETS BV (NL) | 2018-05-02 | — | — | EP | disclosed |
| US-20170145054-A1 | PROCESS FOR THE PRODUCTION OF A DIPEPTIDE DERIVATIVE | DSM IP ASSETS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| EP-2960232-A1 | Process for the production of a dipeptide derivative | DSM IP Assets B.V. (NL) | 2015-12-30 | — | — | EP | disclosed |
| EP-1628965-B1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | WILEX AG (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-7807681-B2 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | WILEX AG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7608623-B2 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | WILEX AG (DE) | 2009-10-27 | — | — | US | disclosed |
| US-20080261998-A1 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | WILEX AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20060142305-A1 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | WILEX AG (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1628965-A1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | Wilex AG (DE) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004103984-A1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | WILEX AG (DE) | 2004-12-02 | — | — | WO | disclosed |
| US-6541497-B1 | Amino acid derivatives of benzoxazin-2-ylaminoalkoxyphenylalkyl compounds | ELI LILLY AND COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-6353027-B1 | ENANTIOMORPHIC AMINE DERIVATIVES FOR TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2002-03-05 | — | — | US | disclosed |
| US-6194446-B1 | NON-INSULIN DEPENDENT DIABETES | ELI LILLY AND COMPANY | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142305-A1 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | PLAU, PLAUR, HPN | SLC1A3 2109/4885SLC1A2 2309/4885SLC1A1 2267/4885 |
| US-10059738-B2 | Process for the production of a dipeptide derivative | VIP, PEPD, DNPEP | SLC1A3 673/4885SLC1A2 1609/4885SLC1A1 555/4885 |
| US-20170145054-A1 | PROCESS FOR THE PRODUCTION OF A DIPEPTIDE DERIVATIVE | VIP, PEPD, DNPEP | SLC1A3 673/4885SLC1A2 1609/4885SLC1A1 555/4885 |
| US-20080261998-A1 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | PLAU, PLAUR, HPN | SLC1A3 2109/4885SLC1A2 2309/4885SLC1A1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.